Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140312 | 0.91 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL1140489 | 0.91 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL1139701 | 0.91 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL1139943 | 0.85 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL3339122 | 0.82 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL3339036 | 0.81 | HPGD (0.53) | MAPK14 | |
| SCHEMBL3110329 | 0.79 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL5276027 | 0.78 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL1139841 | 0.77 | MAPK14 (0.63) | MAPK14 | |
| SCHEMBL5276315 | 0.77 | MAPK14 (0.48) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7696215-B2 | 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL2RA | MAPK14 1418/4885ROCK1 1772/4885 |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL1B | MAPK14 1400/4885ROCK1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.